These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 28562332)
21. Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma. Parker AS; Eckel-Passow JE; Serie D; Hilton T; Parasramka M; Joseph RW; Wu KJ; Cheville JC; Leibovich BC Eur Urol; 2014 Nov; 66(5):929-35. PubMed ID: 24388441 [TBL] [Abstract][Full Text] [Related]
22. Dot1l expression predicts adverse postoperative prognosis of patients with clear-cell renal cell carcinoma. Qu Y; Liu L; Wang J; Xi W; Xia Y; Bai Q; Xiong Y; Long Q; Xu J; Guo J Oncotarget; 2016 Dec; 7(51):84775-84784. PubMed ID: 27713173 [TBL] [Abstract][Full Text] [Related]
23. A novel 10 glycolysis-related genes signature could predict overall survival for clear cell renal cell carcinoma. Xing Q; Zeng T; Liu S; Cheng H; Ma L; Wang Y BMC Cancer; 2021 Apr; 21(1):381. PubMed ID: 33836688 [TBL] [Abstract][Full Text] [Related]
24. High expression of interleukin-11 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma. Pan D; Xu L; Liu H; Zhang W; Liu W; Liu Y; Fu Q; Xu J Cancer Sci; 2015 May; 106(5):592-7. PubMed ID: 25702890 [TBL] [Abstract][Full Text] [Related]
25. β1,6-N-acetylglucosaminyltransferase V predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection. Liu Y; Liu H; Liu W; Zhang W; An H; Xu J World J Urol; 2015 Nov; 33(11):1791-9. PubMed ID: 25630622 [TBL] [Abstract][Full Text] [Related]
26. High CLEC-2 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma. Xiong Y; Liu L; Xia Y; Wang J; Xi W; Bai Q; Qu Y; Long Q; Xu J; Guo J Oncotarget; 2016 Sep; 7(39):63661-63668. PubMed ID: 27564117 [TBL] [Abstract][Full Text] [Related]
27. Elevated Expression of N-Acetylgalactosaminyltransferase 10 Predicts Poor Survival and Early Recurrence of Patients with Clear-Cell Renal Cell Carcinoma. Wu Q; Yang L; Liu H; Zhang W; Le X; Xu J Ann Surg Oncol; 2015 Jul; 22(7):2446-53. PubMed ID: 25391266 [TBL] [Abstract][Full Text] [Related]
29. High expression of chemokine CCL2 is associated with recurrence after surgery in clear-cell renal cell carcinoma. Yang Y; Zhai C; Chang Y; Zhou L; Shi T; Tan C; Xu L; Xu J Urol Oncol; 2016 May; 34(5):238.e19-26. PubMed ID: 26749463 [TBL] [Abstract][Full Text] [Related]
30. Differential expression in clear cell renal cell carcinoma identified by gene expression profiling. Lane BR; Li J; Zhou M; Babineau D; Faber P; Novick AC; Williams BR J Urol; 2009 Feb; 181(2):849-60. PubMed ID: 19095258 [TBL] [Abstract][Full Text] [Related]
31. CD276 is a promising biomarker for the prognosis of clear cell renal cell carcinoma. Yu YH; Xu JH; Chen H; Lin YX; Ou-Yang J; Zhang ZY Kaohsiung J Med Sci; 2024 Oct; 40(10):926-933. PubMed ID: 39210603 [TBL] [Abstract][Full Text] [Related]
32. High expression of Solute Carrier Family 1, member 5 (SLC1A5) is associated with poor prognosis in clear-cell renal cell carcinoma. Liu Y; Yang L; An H; Chang Y; Zhang W; Zhu Y; Xu L; Xu J Sci Rep; 2015 Nov; 5():16954. PubMed ID: 26599282 [TBL] [Abstract][Full Text] [Related]
33. Granulocyte macrophage colony-stimulating factor predicts postoperative recurrence of clear-cell renal cell carcinoma. Chang Y; Xu L; Zhou L; Fu Q; Liu Z; Yang Y; Lin Z; Xu J Oncotarget; 2016 Apr; 7(17):24527-36. PubMed ID: 27016418 [TBL] [Abstract][Full Text] [Related]
34. p21-activated kinase 1 predicts recurrence and survival in patients with non-metastatic clear cell renal cell carcinoma. Zhu Y; Xu L; An H; Liu W; Wang Z; Xu J Int J Urol; 2015 May; 22(5):447-53. PubMed ID: 25711487 [TBL] [Abstract][Full Text] [Related]
36. A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma. Morgan TM; Mehra R; Tiemeny P; Wolf JS; Wu S; Sangale Z; Brawer M; Stone S; Wu CL; Feldman AS Eur Urol; 2018 May; 73(5):763-769. PubMed ID: 29249291 [TBL] [Abstract][Full Text] [Related]
37. FSIP2 can serve as a predictive biomarker for Clear Cell Renal Cell Carcinoma prognosis. Zhang Y; Zhu X; Qiao X; Sun L; Tian Y; Yang Y; Zhao Y; Liu C Int J Med Sci; 2020; 17(17):2819-2825. PubMed ID: 33162809 [No Abstract] [Full Text] [Related]
38. Critical analysis of a simplified Fuhrman grading scheme for prediction of cancer specific mortality in patients with clear cell renal cell carcinoma--Impact on prognosis. Becker A; Hickmann D; Hansen J; Meyer C; Rink M; Schmid M; Eichelberg C; Strini K; Chromecki T; Jesche J; Regier M; Randazzo M; Tilki D; Ahyai S; Dahlem R; Fisch M; Zigeuner R; Chun FK Eur J Surg Oncol; 2016 Mar; 42(3):419-25. PubMed ID: 26520403 [TBL] [Abstract][Full Text] [Related]
39. S100A8 Expression May Have a Prognostic Value in CCRCC Reflecting TNM Staging and Fuhrman Nuclear Grade. An HJ; Koh HM; Song DH Anticancer Res; 2019 Sep; 39(9):4681-4685. PubMed ID: 31519567 [TBL] [Abstract][Full Text] [Related]
40. Low CCL17 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma. Xiong Y; Liu L; Xia Y; Wang J; Xi W; Bai Q; Qu Y; Xu J; Guo J BMC Cancer; 2017 Feb; 17(1):117. PubMed ID: 28178948 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]